# Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

> **NCT05767346** · PHASE3 · COMPLETED · sponsor: **Cytokinetics** · enrollment: 175 (actual)

## Conditions studied

- Obstructive Hypertrophic Cardiomyopathy (oHCM)

## Interventions

- **DRUG:** Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)
- **DRUG:** Placebo to match aficamten
- **DRUG:** Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)
- **DRUG:** Placebo to match metoprolol succinate

## Key facts

- **NCT ID:** NCT05767346
- **Lead sponsor:** Cytokinetics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-20
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-03-28
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2025-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05767346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05767346, "Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05767346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*